Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010008 | 0.98 | L3MBTL1 (1.00) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL2673561 | 0.98 | L3MBTL1 (0.91) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Bromide SCHEMBL5330234 | 0.98 | L3MBTL1 (0.91) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL25383397 | 0.95 | L3MBTL1 (0.95) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL2674470 | 0.95 | L3MBTL1 (0.95) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL8860545 | 0.90 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL11598668 | 0.90 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL3926676 | 0.88 | L3MBTL1 (0.75) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL4710262 | 0.86 | L3MBTL1 (0.72) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL2877981 | 0.86 | L3MBTL1 (0.72) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| US-10562842-B2 | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | UNIVERSITE D'AIX-MARSEILLE (FR) | 2020-02-18 | — | — | US | claimed |
| CN-109923114-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2019-06-21 | — | — | CN | claimed |
| EP-2678307-B1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIV AIX MARSEILLE (FR) | 2018-04-04 | — | — | EP | claimed |
| US-20170015617-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2017-01-19 | — | — | US | claimed |
| US-9328093-B2 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2016-05-03 | — | — | US | claimed |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2015-03-12 | — | — | US | claimed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | claimed |
| EP-2523938-B1 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2014-09-03 | — | — | EP | claimed |
| US-20140128335-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-05-08 | — | — | US | claimed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | claimed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | claimed |
| EP-0691961-B1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | DU PONT PHARM CO (US) | 2002-02-13 | — | — | EP | claimed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| EP-0794827-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | Pharmacia Biotech AB (SE) | 1997-09-17 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996016724-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | PHARMACIA BIOTECH AB (SE) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | L3MBTL1 3428/4885ALDH1A1 1671/4885MAPT 2035/4885 |
| US-20140128335-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | ABCC1, ABCB11, ABCB1 | L3MBTL1 4203/4885ALDH1A1 3021/4885MAPT 4030/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | L3MBTL1 4313/4885ALDH1A1 2773/4885MAPT 3167/4885 |
| US-20170015617-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | ABCC1, ABCB11, ABCB1 | L3MBTL1 4203/4885ALDH1A1 3021/4885MAPT 4030/4885 |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | L3MBTL1 2442/4885ALDH1A1 3216/4885MAPT 704/4885 |
| US-10562842-B2 | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | ABCC1, ABCB11, ABCB1 | L3MBTL1 4203/4885ALDH1A1 3021/4885MAPT 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.